Cargando…
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
Lung cancer is one of the deadliest and most common malignancies in the world, representing one of the greatest challenges in cancer treatment. Immunotherapy is rapidly changing standard treatment schedule and outcomes for patients with advanced malignancies. However, several ongoing studies are sti...
Autores principales: | Carbone, Carmine, Piro, Geny, Di Noia, Vincenzo, D'Argento, Ettore, Vita, Emanuele, Ferrara, Miriam Grazia, Pilotto, Sara, Milella, Michele, Cammarota, Giovanni, Gasbarrini, Antonio, Tortora, Giampaolo, Bria, Emilio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6885300/ https://www.ncbi.nlm.nih.gov/pubmed/31827379 http://dx.doi.org/10.1155/2019/7652014 |
Ejemplares similares
-
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
por: Ferrara, Miriam Grazia, et al.
Publicado: (2020) -
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021) -
Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020) -
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer
por: Stefani, Alessio, et al.
Publicado: (2022) -
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
por: Di Noia, Vincenzo, et al.
Publicado: (2020)